This invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula 11, wherein the substituents G, L, U, and Q have the meaning as defined in the specification.
The present invention relates to novel compounds suitable for or already radiolabeled with
18
F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.
The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and/or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.
The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.
Single step method of radiofluorination of biologically active compounds or biomolecules
申请人:Bayer Schering Pharma Aktiengesellschaft
公开号:EP1985624A2
公开(公告)日:2008-10-29
The invention relates to novel single step method of radiofluorination of biologically active compounds or biomolecules for obtaining radiopharmaceutical, especially for use in Positron Emitting Tomography (PET) imaging.